Immunomedics, Inc., (Nasdaq: IMMU) announced that the abstract on sacituzumab govitecan (IMMU-132), the Company’s lead antibody-drug conjugate (ADC), in patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE